Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Stress testing in patients with chronic kidney disease: The need for ancillary markers for effective risk stratification and prognosis

Bangalore, Sripal
PMID: 26297196
ISSN: 1532-6551
CID: 1741952

2013 ACC/AHA GUIDELINE RECOMMENDATION ON BLOOD CHOLESTEROL REVISITED: PERCENT LDL-C REDUCTION OR ATTAINED LDL-C LEVEL OR BOTH FOR PROGNOSIS? [Meeting Abstract]

Bangalore, Sripal; Fayyad, Rana; Kastelein, John; Laskey, Rachel; Amarenco, Pierre; DeMicco, David; Waters, David
ISI:000375328801681
ISSN: 0735-1097
CID: 2962452

GENDER DISPARITY IN THE NEW ACC/AHA RECOMMENDED REPERFUSION TIME IN ACUTE STEMI PATIENTS [Meeting Abstract]

Roswell, Robert; Kunkes, Jordan; Ghumman, Muhammad; Bangalore, Sripal
ISI:000375328800100
ISSN: 1558-3597
CID: 2793572

DOSE-DEPENDENT EFFECT OF ATORVASTATIN ON LONG-TERM KIDNEY FUNCTION AND ASSOCIATED CARDIOVASCULAR OUTCOMES [Meeting Abstract]

Vogt, L; Bangalore, S; Fayyad, R; Laskey, R; Hovingh, GK; DeMicco, DA; Waters, D
ISI:000360100600031
ISSN: 1879-1484
CID: 2792632

LIPID LOWERING EFFICACY OF ATORVASTATIN IS RELATED TO IMPROVEMENT OF KIDNEY FUNCTION OVER TIME [Meeting Abstract]

Vogt, Liffert; Bangalore, Sripal; Fayyad, Rana; Laskey, Rachel; Hovingh, GKees; DeMicco, David A; Waters, David D
ISI:000361215100377
ISSN: 1460-2385
CID: 2391202

When Results Also Allow the Opposite Conclusion... [Letter]

Messerli, Franz H; Bangalore, Sripal; Rimoldi, Stefano F
PMID: 26508708
ISSN: 1879-1913
CID: 2039362

Impaired myocardial oxygenation response to stress in patients with chronic kidney disease [Meeting Abstract]

Parnham, S; Gleadle, J; Bangalore, S; Grover, S; Perry, R; Woodman, R; De, Pasquale C; Selvanayagam, J
Background: Coronary artery disease (CAD) and left ventricular hypertrophy (LVH) are prevalent in the chronic kidney disease (CKD) and renal transplant population. We hypothesised that the myocardial oxygenation response to stress would be impaired in CKD Methods: Fifty-three subjects: twenty-three subjects with CKD, ten renal transplant (RT) recipients, ten hypertensive (HT) controls, and ten normal controls without known heart disease underwent CMR scanning at 3T. The RT and HT groups also had late gadolinium CMR to assess infarction/ replacement fibrosis. The CKD group underwent 2D echocardiography strain to assess fibrosis. Results: A total of 2898 myocardial segments (1200 segments in CKD patients, 552 segments in RT, 480 segments in HT, and 666 segments in normal controls) were compared using linear mixed modelling. Diabetes mellitus (p= 0.47) and hypertension (p= 0.57) were similar between CKD, RT, and HT groups. The mean BOLD SI change was significantly lower in the CKD and RT groups compared to HT controls and normal controls (-0.89 +/- 10.63 in CKD versus 5.66 +/- 7.87 in RT versus 15.54 +/- 9.58 in HT controls, p< 0.0001). BOLD SI Change was associated with eGFR (beta= 0.16, 95% CI= 0.10 to 0.22, p<0.0001). Left ventricular mass index and left ventricular septal wall diameter was similar between the CKD pre-dialysis, RT, and HT groups. None of the CKD patients had impaired global longitudinal strain (GLS) and none of the RT group had late gadolinium hyperenhancement. Conclusion: Myocardial oxygenation response to stress is impaired in CKD and RT patients, and unlikely to be solely accounted for by the presence of diabetes mellitus
EMBASE:72103360
ISSN: 1443-9506
CID: 1905162

Teachable moment or missed opportunity? [Editorial]

Messerli, Franz H; Bangalore, Sripal; Meier, Bernhard
ISI:000366489500006
ISSN: 1522-9645
CID: 1896092

Evidence-Based Management of Stable Ischemic Heart Disease: Challenges and Confusion

Bangalore, Sripal; Maron, David J; Hochman, Judith S
PMID: 26547460
ISSN: 1538-3598
CID: 1834492

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

Kaul, Upendra; Bangalore, Sripal; Seth, Ashok; Arambam, Priyadarshini; Abhaychand, Rajpal K; Patel, Tejas M; Banker, Darshan; Abhyankar, Atul; Mullasari, Ajit S; Shah, Sanjay; Jain, Rajneesh; Kumar, Premchand R; Bahuleyan, C G
BACKGROUND: The choice of drug-eluting stent in the treatment of patients with diabetes mellitus and coronary artery disease who are undergoing percutaneous coronary intervention (PCI) has been debated. Previous studies comparing paclitaxel-eluting stents with stents eluting rapamycin (now called sirolimus) or its analogues (everolimus or zotarolimus) have produced contradictory results, ranging from equivalence between stent types to superiority of everolimus-eluting stents. METHODS: We randomly assigned 1830 patients with diabetes mellitus and coronary artery disease who were undergoing PCI to receive either a paclitaxel-eluting stent or an everolimus-eluting stent. We used a noninferiority trial design with a noninferiority margin of 4 percentage points for the upper boundary of the 95% confidence interval of the risk difference. The primary end point was target-vessel failure, which was defined as a composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization at the 1-year follow-up. RESULTS: At 1 year, paclitaxel-eluting stents did not meet the criterion for noninferiority to everolimus-eluting stents with respect to the primary end point (rate of target-vessel failure, 5.6% vs. 2.9%; risk difference, 2.7 percentage points [95% confidence interval, 0.8 to 4.5]; relative risk, 1.89 [95% confidence interval, 1.20 to 2.99]; P=0.38 for noninferiority). There was a significantly higher 1-year rate in the paclitaxel-eluting stent group than in the everolimus-eluting stent group of target-vessel failure (P=0.005), spontaneous myocardial infarction (3.2% vs. 1.2%, P=0.004), stent thrombosis (2.1% vs. 0.4%, P=0.002), target-vessel revascularization (3.4% vs. 1.2%, P=0.002), and target-lesion revascularization (3.4% vs. 1.2%, P=0.002). CONCLUSIONS: In patients with diabetes mellitus and coronary artery disease undergoing PCI, paclitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they resulted in higher rates of target-vessel failure, myocardial infarction, stent thrombosis, and target-vessel revascularization at 1 year. (Funded by Boston Scientific; TUXEDO-India Clinical Trials Registry-India number, CTRI/2011/06/001830).
PMID: 26466202
ISSN: 1533-4406
CID: 1816562